Ovid Therapeutics Inc (OVID)
3.15
-0.12
(-3.82%)
USD |
NASDAQ |
May 17, 16:00
3.15
0.00 (0.00%)
After-Hours: 20:00
Ovid Therapeutics Revenue (Quarterly): 0.148M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.148M |
| December 31, 2023 | 0.1416M |
| September 30, 2023 | 0.109M |
| June 30, 2023 | 0.075M |
| March 31, 2023 | 0.066M |
| December 31, 2022 | 0.0463M |
| September 30, 2022 | 0.0111M |
| June 30, 2022 |
| Date | Value |
|---|---|
| March 31, 2022 | 1.445M |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | 208.38M |
| December 31, 2020 | 5.703M |
| September 30, 2020 | 6.914M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.0111M
Minimum
Sep 2022
208.38M
Maximum
Mar 2021
20.28M
Average
0.1416M
Median
Dec 2023
Revenue (Quarterly) Benchmarks
| Ligand Pharmaceuticals Inc | 30.98M |
| NovaBay Pharmaceuticals Inc | 2.631M |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
| Theriva Biologics Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -11.69M |
| Total Expenses (Quarterly) | 17.56M |
| EPS Diluted (Quarterly) | -0.17 |
| Enterprise Value | 133.22M |
| Profit Margin (Quarterly) | -7.90K% |
| Earnings Yield | -23.17% |
| Normalized Earnings Yield | -23.17 |